These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35880395)

  • 1. Treatment horizon in multiple myeloma.
    Soekojo CY; Chng WJ
    Eur J Haematol; 2022 Nov; 109(5):425-440. PubMed ID: 35880395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 7. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel approaches to the treatment of multiple myeloma.
    Maples KT; Scott SA; Lonial S
    Clin Adv Hematol Oncol; 2023 May; 21(5):247-256. PubMed ID: 37145495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
    Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
    Front Immunol; 2022; 13():839097. PubMed ID: 35320942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
    Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
    J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging agents and regimens for multiple myeloma.
    Yang Y; Li Y; Gu H; Dong M; Cai Z
    J Hematol Oncol; 2020 Nov; 13(1):150. PubMed ID: 33168044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Future therapeutic strategies for multiple myeloma].
    Ishida T
    Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multiple myeloma: a focus on drugs under development].
    Sunami K
    Rinsho Ketsueki; 2020; 61(5):520-527. PubMed ID: 32507818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of potential antibody-based therapies for myeloma.
    Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
    Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.